- A total of 12 abstracts, including four Best of Cosmetic
Abstracts, demonstrate Allergan Aesthetics' commitment to patient
outcomes and detailed insights and understanding of key concerns
across differentiated patient segments
- Insightful panel discussion with Dr. Kavita Mariwalla, ASDS President Elect (2026)
and double board-certified dermatologist, on impact of social media
on patient experience and expectations when considering aesthetic
treatment
IRVINE,
Calif., Oct. 16, 2024 /PRNewswire/ -- Allergan
Aesthetics, an AbbVie company (NYSE: ABBV), will present data
highlighting efficacy, safety and patient-reported outcomes across
its facial injectable portfolio during the 2024 American Society of
Dermatologic Surgery (ASDS) Annual Meeting, October 17-20, 2024 in Orlando, Florida. Presentations and a panel
discussion demonstrate Allergan Aesthetics' commitment to
understanding patient sentiment and developing differentiated
treatments to address key aesthetic concerns.
"Allergan Aesthetics has one of the most robust portfolios for
aesthetics innovation and continues to lead the industry in
innovation. Conducting research that helps ensure safe and optimal
outcomes for our differentiated treatments is critical to the
future of the aesthetics industry," said, Sara Sangha, Head of U.S. Aesthetics Medical
Affairs at Allergan Aesthetics. "As the global aesthetic brand that
medical providers and patients know and trust, our commitment to
serving and growing the industry with new products, indications and
appeal to diverse and new patients is advanced by the research and
data presented at ASDS."
Notable presentations, including the below selected as "Best of"
Cosmetic, highlight efficacy and safety data of facial injectables,
including:
- Safety and patient-reported outcomes from a Phase 3 open-label
extension study of onabotulinumtoxinA (BOTOX® Cosmetic) for the
treatment of platysma bands.
- Patient satisfaction after receiving JUVEDERM VOLUMA XC for
injection in the temple region to improve moderate to severe temple
hollowing in adults over the age of 21.
Additional presentations, including one selected as "Best of"
Cosmetic, showcase in-depth detail from a 4,000-subject study
across ethnic, racial and gender groups and highlighting key
aesthetic concerns by patient segments. The findings from this
study, the largest in the U.S., suggest that interest in
professionally administered aesthetic treatments for face and body
vary among demographic groups and differ from what current
aesthetic paradigms suggest.
Data from the following self-identified patient demographics was
included:
- Females
- Black
- Hispanic/Latina
- White
- Asian
- Males
Allergan Aesthetics is also hosting a thought-provoking
conversation around social integrity in the aesthetics industry as
featured in 'Moving the Needle on Ethics'—the industry-first global
collation of thought-leadership essays from Allergan Aesthetics.
The panel will spark an open dialogue focusing on the trends in
social media usage to promote aesthetics products and procedures
and the importance of ethical practices to industry integrity.
The conversation will be led by author, Dr. Mariwalla, and
feature expert voices including Dr. Evan
Rieder, double-board-certified dermatologist and
psychiatrist, Dr. DiAnne Davis,
board-certified dermatologist and Dr. Fatima Fahs, board-certified dermatologist and
social media expert as moderator.
This panel will take place on Thursday,
October 17th at 12 noon
ET in the Special Events Room.
Allergan Aesthetics abstracts at ASDS 2024 are outlined below.
The 2024 ASDS video posters can be viewed in "Video Oral Abstract"
kiosk areas in the Exhibit Hall.
|
"Best of Cosmetic" Live
Presentation
Saturday October 19,
2024 at 8:30-9:30 AM Gatlin Ballroom A3/A4
|
|
Abstract
Title
|
Physician Name/Primary
Author
|
|
Hyaluronic Acid Filler
VYC-20L for Correction of Temple
Hollowing Yields High Satisfaction, Improvement in Facial
and Temple Appearance, and Sustained Effect Across
Age, Gender, and Skin Phototypes
|
José R Montes,
MD
|
|
Patient-Reported
Outcomes Across Repeat Treatments for
Moderate to Severe Platysma Prominence with
OnabotulinumtoxinA in a Long-term, Phase 3, Open-label
Extension Study
|
Shannon Humphrey, MD,
FRCPC, FAAD
|
|
Repeat Treatments of
Moderate to Severe Platysma
Prominence With OnabotulinumtoxinA Has a Favorable
Safety Profile in a Long-term, Phase 3, Open-label
Extension Study
|
Terrence Keaney, MD,
FAAD
|
|
Interest in
professionally administered aesthetic treatments
for face and body: Results from Black female-identifying
respondents of a large survey of aesthetically inclined
adults in the US
|
Michelle Henry,
MD
|
|
Maximum Difference
VIDEO Poster Abstract Presentation
Can be viewed in "Video
Oral Abstract" kiosk areas in the Exhibit Hall
|
|
Abstract
Title
|
Physican Name/Primary
Author
|
|
Interest in
professionally administered aesthetic treatments
for face and body: Results from Hispanic/Latina female-
identifying respondents of a large survey of aesthetically
inclined adults in the US
|
Vivian Bucay, MD,
FAADboard-certified dermatologist
|
|
Interest in
professionally administered aesthetic treatments
for face and body: Results from White female-identifying
respondents to a large survey of aesthetically inclined
adults in the US
|
Deirdre Hooper,
MD
|
|
Interest in
professionally administered aesthetic treatments
for face and body: Results from Asian female-identifying
respondents of a large survey of aesthetically inclined
adults in the US
|
Annie Chiu, MD,
FAAD
|
|
Interest in
professionally administered aesthetic treatments
for face and body: Results from male and female
respondents of a large survey of aesthetically inclined
adults in the US
|
Terrence Keaney, MD,
FAAD
|
|
Facial – VIDEO Poster
Abstract Presentation
Can be viewed in "Video
Oral Abstract" kiosk areas in the Exhibit Hall
|
|
Abstract
Titles
|
Physican Name/Primary
Author
|
|
Infraorbital and
Periorbital Rejuvenation With Sequential
Use of Hyaluronic Acid-Fillers and OnabotulinumtoxinA
|
Samira Baharlou, MD
|
|
Patient-Reported
Outcomes After Infraorbital and
Periorbital Rejuvenation Using Sequential Hyaluronic Acid-
Fillers and OnabotulinumtoxinA Treatments
|
Gregory Goodman, MD
|
|
OnabotulinumtoxinA for
the Treatment of Platysma
Prominence: Patient-Reported Outcomes From Two
Phase 3 Multicenter, Randomized, Double-Blind, Placebo-
Controlled Studies
|
Joely Kaufman,
MD
|
|
Treating Platysma
Prominence with OnabotulinumtoxinA:
Safety and Efficacy Results from a Phase 3 Multicenter,
Randomized, Double-blind, Placebo-Controlled Study
|
Sabrina Fabi,
MD
|
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop,
manufacture, and market a portfolio of leading aesthetics brands
and products. Our aesthetics portfolio includes facial injectables,
body contouring, plastics, skin care, and more. Our goal is to
consistently provide our customers with innovation, education,
exceptional service, and a commitment to excellence, all with a
personal touch. For more information, visit
www.allerganaesthetics.com
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
LinkedIn, Facebook, Instagram, X (formerly Twitter), and
YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions and uses
of future or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-to-present-new-data-at-2024-american-society-for-dermatologic-surgery-asds-to-showcase-depth-across-facial-aesthetics-and-insight-into-patient-perception-302277332.html
SOURCE AbbVie